NL-OMON47684已完成2 期
A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren*s Disease - Repurposing anti-TNF for treating Dupuytren*s disease. RIDD
niversity of Oxford, Research Services, Clinical Trials and Research Governance, Joint Research Office, Boundary Brook House0 个研究点目标入组 35 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Participant is willing and able to give informed consent for participation in the study.
- •* Male or Female, aged 18 years or above.
- •* Participants with early disease nodules who have shown or reported progression of the disease in the previous 6 months with flexion deformities of their fingers of *30° at the metacarpophalangeal and/or at the proximal interphalangeal joint, i.e. total flexion deformity of up to 60°.
- •* The DD nodule to be treated must be distinct and identifiable.
- •* Female participants of child bearing potential, and male participants whose partner is of child bearing potential, must be willing to ensure that they or their partner use effective contraception throughout the treatment period and for 5 months following the last research injection.
- •* Participant results from safety screening tests within normal ranges within 12 weeks of enrolment.
- •* Able (in the Investigators opinion) and willing to comply with all study requirements.
- •* Willing to allow his or her general practitioner to be notified of participation in the study.
- •* Sufficient language fluency to ensure informed consent is obtained and to complete the questionnaires pertaining to hand function.
排除标准
- •* Participant has previously had fasciectomy, dermofasciectomy, needle fasciotomy, collagenase injection, steroid injection to the digit to be treated or radiotherapy to to treat Dupuytren's disease in the hand concerned.
- •* Female participant who is pregnant, lactating or planning pregnancy during the course of the study and for 5 months following last injection.
- •* Male participant who is planning a pregnancy during the course of the study and for 5 months following last injection.
- •* Significant renal or hepatic impairment.
- •* Participant who has ever been diagnosed with cancer, is terminally ill or is inappropriate for placebo medication.
- •* Systemic inflammatory disorder such as RA or inflammatory bowel disease.
- •* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant*s ability to participate in the study.
- •* Participated in another research study involving an investigational medicinal product in the past 12 weeks.
- •* Known allergy to any anti-TNF agent.
- •* Have HIV or hepatitis B or C.
- •* Known to have an infection or history of repeated infections.
- •* History of Tuberculosis (TB).
- •* Have Multiple Sclerosis (MS) or other demyelinating disease.
- •* History of local injection site reactions.
- •* Needle phobia.
- •* Have moderate or severe heart failure.
- •* Have known lung fibrosis (thickening of lung tissue).
- •* Being treated with concomitant biologic DMARDS.
- •* Have received a live vaccine within the previous 4 weeks. Participants may receive concurrent vaccinations but must avoid the use of live vaccines for 12 weeks after their last injection.
- •* Patients at risk of Hepatitis B infection.
研究者
相似试验
进行中（未招募）
1 期
Repurposing anti-TNF for treating Dupuytren’s disease.EUCTR2015-001780-40-GBniversity of Oxford, Clinical Trials and Research Governance228
进行中（未招募）
1 期
A clinical trial to investigate the effects of a product, fibrinogen concentrate, to assist with rapid clotting of the blood, in patients with major bleeding caused by trauma.Trauma patients whereby the local major haemorrhage protocol has been activatedMedDRA version: 18.0 Level: LLT Classification code 10044461 Term: Trauma System Organ Class: 100000004863EUCTR2015-000875-28-GBHS Blood & Transplant48
进行中（未招募）
不适用
A multi-centre, randomised, double blind, placebo-controlled, parallel group, single dose, pilot study of the efficacy of 0.6 mg Amylmetacresol BP (AMC) and 1.2mg 2,4-Dichlorobenzyl alcohol (DCBA) throat lozenges in the relief of sore throat due to upper respiratory tract infection. - 0.6 mg AMC and 1.2 mg DCBA Lozenges Pilot Efficacy StudySore throatMedDRA version: 9.1Level: LLTClassification code 10041367Term: Sore throatEUCTR2008-005059-67-GBReckitt Benckiser Healthcare UK Ltd
进行中（未招募）
2 期
Evaluate the effectiveness and safety of Cpn10 in subjects with moderate to severe rheumatoid arthritis despite treatment with methotrexateACTRN12608000208303CBio Limited150
已完成
不适用
A Randomised Control Trial in children aged 12-23 months consuming Growing up Milk - lite or cow's milk.ACTRN12614000918628The University of Auckland, Faculty of Medical and Health Science160